23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › BridgeBio Pharma, Inc. › 2025-2026

BridgeBio Pharma, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and BridgeBio Pharma, Inc.’s Form 8-K, filed June 26, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Reported items
  • 465Asset managers, any item
  • 4,402Fund votes
  • June 22, 2026Meeting date

Results at a glance

Meeting of June 22, 2026: 6 items on BridgeBio Pharma, Inc.’s Form 8-K, filed June 26, 2026: 3 approved · 3 passed (calculated).

Dissent

Notable dissent: 1 director (19.9% against); 1 equity or compensation plan (17.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BridgeBio Pharma, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by BridgeBio Pharma, Inc.

These tallies are BridgeBio Pharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 26, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BridgeBio Pharma, Inc. — official shareholder meeting results, meeting held June 22, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: James C. Momtazee 156,790,852---- 4,316,01814,599,487 97%Passed (calculated)—
Elect Director: Frank P. McCormick, Ph.D. 153,020,532---- 8,086,33814,599,487 95%Passed (calculated)—
Elect Director: Hannah A. Valantine, M.D. 129,081,930---- 32,024,94014,599,487 80%Passed (calculated)—
2. Non-binding Advisory Vote on Compensation of Named Executive Officers 152,949,5776,938,0801,219,213 --14,599,487 96%Approved—
4. Ratification of Appointment of Independent Registered Accounting Firm 175,420,234203,31082,813 ---- 99.9%Approved—
5. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan 132,402,78627,350,5371,353,547 --14,599,487 83%Approved—

Source: BridgeBio Pharma, Inc., Form 8-K, filed with the SEC on June 26, 2026 — read the filing on EDGAR.

How asset managers voted at the BridgeBio Pharma, Inc. 2025-2026 meeting

465 asset managers disclosed a vote on at least one BridgeBio Pharma, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BridgeBio Pharma, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Frank P. McCormick, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 9 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 153,020,532WITHHELD: 8,086,338
Details: description as filed, official tally, votes by 125 asset managers

Description as filed by funds: To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: Frank P. McCormick, Ph.D.

BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: Frank P. McCormick, Ph.D.”): 153,020,532 for, 8,086,338 withheld, per its Form 8-K filed June 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 125 asset managers below reported 61,342,754 for, 3,189,415 withheld, 86,559 abstained, 204 not voted.

FOR
FOR: 61,342,754ABSTAIN: 86,559WITHHOLD: 3,189,415NOT VOTED: 204
Largest asset managers voting on “To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantin” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard17,065,8530 249,383For
Fidelity6,274,2850 00For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND5,303,7190 00For
Invesco3,054,1070 00For
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,4100 0447For
Delaware/Macquarie1,134,6520 00For
Columbia Threadneedle1,052,5230 00For
Lord Abbett942,1450 00For
American Century831,1140 00For
JPMorgan809,8540 00For
Capital Group763,7020 00For
Principal458,2360 0257,703Mixed
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National678,4170 4,2360For
Allspring649,9050 00For
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable363,6180 0267,012Mixed
AllianceBernstein00 0574,183Withhold
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason442,5420 00For
MUTUAL FUND SERIES TRUST437,1300 00For

Showing the 25 largest of 125 asset managers. All 125 are in the interactive database (link above).

Elect Director: Hannah A. Valantine, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 9 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD
FOR: 129,081,930WITHHELD: 32,024,940
Details: description as filed, official tally, votes by 125 asset managers

Description as filed by funds: To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: Hannah A. Valantine, M.D.

BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: Hannah A. Valantine, M.D.”): 129,081,930 for, 32,024,940 withheld, per its Form 8-K filed June 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 125 asset managers below reported 52,311,370 for, 11,558,547 withheld, 748,812 abstained, 204 not voted.

FORWITHHOLD
FOR: 52,311,370ABSTAIN: 748,812WITHHOLD: 11,558,547NOT VOTED: 204
Largest asset managers voting on “To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantin” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard17,002,8210 8372,356For
Fidelity6,214,1850 060,100For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND3,914,1050 01,389,614Mixed
Invesco3,054,1070 00For
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,4100 0447For
Delaware/Macquarie00 01,134,652Withhold
Columbia Threadneedle00 01,052,523Withhold
Lord Abbett942,1450 00For
American Century00 0831,114Withhold
JPMorgan809,8540 00For
Capital Group763,7020 00For
Principal00 0715,939Withhold
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National569,4730 113,1800Mixed
Allspring00 0649,905Withhold
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable363,6180 0267,012Mixed
AllianceBernstein00 0574,183Withhold
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason436,5570 05,985For
MUTUAL FUND SERIES TRUST437,1300 00For

Showing the 25 largest of 125 asset managers. All 125 are in the interactive database (link above).

Elect Director: James C. Momtazee

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 9 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 156,790,852WITHHELD: 4,316,018
Details: description as filed, official tally, votes by 125 asset managers

Description as filed by funds: To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: James C. Momtazee

BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: James C. Momtazee”): 156,790,852 for, 4,316,018 withheld, per its Form 8-K filed June 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 125 asset managers below reported 62,663,287 for, 1,887,749 withheld, 67,692 abstained, 204 not voted.

FOR
FOR: 62,663,287ABSTAIN: 67,692WITHHOLD: 1,887,749NOT VOTED: 204
Largest asset managers voting on “To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantin” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard17,075,2480 130For
Fidelity6,274,2850 00For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND5,303,7190 00For
Invesco3,054,1070 00For
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,8570 00For
Delaware/Macquarie1,134,6520 00For
Columbia Threadneedle1,052,5230 00For
Lord Abbett942,1450 00For
American Century831,1140 00For
JPMorgan809,8540 00For
Capital Group763,7020 00For
Principal458,2360 0257,703Mixed
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National678,4170 4,2360For
Allspring649,9050 00For
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable363,6180 0267,012Mixed
AllianceBernstein00 0574,183Withhold
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason442,5420 00For
MUTUAL FUND SERIES TRUST437,1300 00For

Showing the 25 largest of 125 asset managers. All 125 are in the interactive database (link above).

Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and…

Official resultCOMPENSATIONReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

83% Approved · of votes cast

FOR 83%AGAINST
FOR: 132,402,786AGAINST: 27,350,537
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares.

BridgeBio Pharma, Inc.’s own tally for this item (“5. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan”): 132,402,786 for, 27,350,537 against — passed, per its Form 8-K filed June 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5 - Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan The Company's stockholders approved the amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (th…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 54,945,059 for, 9,610,820 against, 272,209 abstained, 204 not voted.

FORAGAINST
FOR: 54,945,059AGAINST: 9,610,820ABSTAIN: 272,209NOT VOTED: 204
Largest asset managers voting on “To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option a” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard16,996,25579,002 40For
Fidelity6,214,18560,100 00For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND3,914,1051,389,614 00Mixed
Invesco3,054,1070 00For
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,8570 00For
Delaware/Macquarie01,134,652 00Against
Columbia Threadneedle1,052,5230 00For
Lord Abbett942,1450 00For
American Century0831,114 00Against
JPMorgan809,8540 00For
Capital Group0763,702 00Against
Principal257,703458,236 00Mixed
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National639,13943,514 00Mixed
Allspring0649,905 00Against
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable630,6300 00For
AllianceBernstein574,1830 00For
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason436,5575,985 00For
MUTUAL FUND SERIES TRUST437,1300 00For

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Non-binding Advisory Vote on Compensation of Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 13 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 152,949,577AGAINST: 6,938,080

Prior year: 75.6% for (June 20, 2025 meeting) ▲ 20.0 pts

Details: description as filed, official tally, votes by 463 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

BridgeBio Pharma, Inc.’s own tally for this item (“2. Non-binding Advisory Vote on Compensation of Named Executive Officers”): 152,949,577 for, 6,938,080 against — passed, per its Form 8-K filed June 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 123 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard17,075,24810 40For
Fidelity6,274,2850 00For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND5,303,7190 00For
Invesco15,9533,038,154 00Against
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,8570 00For
Delaware/Macquarie1,134,6520 00For
Columbia Threadneedle1,052,5230 00For
Lord Abbett942,1450 00For
American Century831,1140 00For
JPMorgan809,8540 00For
Capital Group0763,702 00Against
Principal715,9390 00For
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National285,365397,288 00Mixed
Allspring649,9050 00For
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable630,6300 00For
AllianceBernstein574,1830 00For
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason442,5420 00For
MUTUAL FUND SERIES TRUST437,1300 00For

Fund voting reports, all 123 managers: 59,858,396 for, 4,534,345 against, 40,813 abstained, 204 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 372 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson18,435,1960 00For
Kohlberg Kravis Roberts & Co. L.P.13,260,9710 00For
VIKING GLOBAL INVESTORS LP11,763,1750 00For
FARALLON CAPITAL MANAGEMENT, L.L.C.5,740,6390 00For
BlackRock5,255,542373 00For
Aisling Capital Management LP5,089,6110 00For
GEODE CAPITAL MANAGEMENT, LLC4,844,0820 00For
Polar Capital Holdings Plc4,789,4220 00For
Invesco15,9534,097,429 00Against
T. Rowe Price3,558,0310 00For
State Street3,482,1030 00For
Fidelity2,340,83788 00For
Charles Schwab1,997,5710 00For
John Hancock1,944,6520 00For
SC US (TTGP), LTD.1,874,0340 00For
FRANKLIN ADVISERS INC1,853,7630 00For
Wellington1,734,5540 00For
AllianceBernstein1,723,9540 00For
Vanguard1,434,4060 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST1,292,1970 00For
PICTET ASSET MANAGEMENT SA1,241,5720 00For
Hood River Capital Management LLC1,140,4330 00For
LORD, ABBETT & CO. LLC1,077,2430 00For
Clearbridge Investments, LLC1,005,7080 00For
DE Shaw976,5350 00For

Institutional-manager reports, all 372 managers: 118,499,568 for, 5,956,173 against, 2,709 not voted, 664,940 mixed, 37,672 1 year. Showing the 25 largest; every one is in the interactive database (link above).

To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

100% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 443 asset managers

Description as filed by funds: To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 120 asset managers voting on “To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the co” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
Fidelity00 00--
BlackRock00 00--
JANUS INVESTMENT FUND00 00--
Invesco00 00--
T. Rowe Price00 00--
Charles Schwab00 00Not Voted
Delaware/Macquarie00 00--
Columbia Threadneedle00 00--
Lord Abbett00 00--
American Century00 00--
JPMorgan00 00--
Capital Group00 00--
Principal00 00--
Manager Directed Portfolios00 00--
Franklin Custodian Funds00 00--
Jackson National00 00--
Allspring00 00--
FRANKLIN STRATEGIC SERIES00 00--
Equitable00 00--
AllianceBernstein00 00--
PRIMECAP Odyssey Funds00 00--
TIAA00 00--
Legg Mason00 00--
MUTUAL FUND SERIES TRUST00 00--

Fund voting reports, all 120 managers: 167,160 for, 40,809 abstained, 204 not voted, 63,814,167 1 year, 248,551 3 year, 29,693 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 355 asset managers voting on “To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the co” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson00 00--
Kohlberg Kravis Roberts & Co. L.P.00 00--
VIKING GLOBAL INVESTORS LP00 00--
FARALLON CAPITAL MANAGEMENT, L.L.C.5,740,6390 00For
BlackRock00 00--
Aisling Capital Management LP00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
Polar Capital Holdings Plc00 00--
Invesco00 00--
T. Rowe Price00 00--
State Street00 00--
Fidelity00 00--
Charles Schwab00 00Not Voted
John Hancock00 00--
FRANKLIN ADVISERS INC00 00--
Wellington00 00--
AllianceBernstein00 00--
Vanguard00 00--
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST00 00--
PICTET ASSET MANAGEMENT SA00 00--
Hood River Capital Management LLC00 00--
LORD, ABBETT & CO. LLC00 00--
Clearbridge Investments, LLC00 00--
DE Shaw00 00--
American Century00 00--

Institutional-manager reports, all 355 managers: 5,954,576 for, 1,327 not voted, 110,174,062 1 year, 5,089,843 2 year, 1,125,454 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 175,420,234AGAINST: 203,310

Prior year: 100.0% for (June 20, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 124 asset managers

Description as filed by funds: To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

BridgeBio Pharma, Inc.’s own tally for this item (“4. Ratification of Appointment of Independent Registered Accounting Firm”): 175,420,234 for, 203,310 against — passed, per its Form 8-K filed June 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 124 asset managers below reported 64,175,657 for, 4,275 against, 40,809 abstained, 204 not voted.

FOR
FOR: 64,175,657AGAINST: 4,275ABSTAIN: 40,809NOT VOTED: 204
Largest asset managers voting on “To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the C” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard17,075,2610 00For
Fidelity6,274,2850 00For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND5,303,7190 00For
Invesco3,054,1070 00For
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,8570 00For
Delaware/Macquarie1,134,6520 00For
Columbia Threadneedle1,052,5230 00For
Lord Abbett942,1450 00For
American Century831,1140 00For
JPMorgan809,8540 00For
Capital Group763,7020 00For
Principal715,9390 00For
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National682,6530 00For
Allspring649,9050 00For
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable630,6300 00For
AllianceBernstein574,1830 00For
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason442,5420 00For
MUTUAL FUND SERIES TRUST437,1300 00For

Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).

Largest BridgeBio Pharma, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 195,707,702 shares outstanding at the time of that meeting.

Fund voting reports: top BridgeBio Pharma, Inc. shareholders by shares voted on “To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 8.72%
2Fidelity 3.21%
3BlackRock 3.17%
4JANUS INVESTMENT FUND 2.71%
5Invesco 1.56%
6T. Rowe Price 1.39%
7Charles Schwab 1.01%
8Delaware/Macquarie 0.58%
9Columbia Threadneedle 0.54%
10Lord Abbett 0.48%
Institutional-manager reports: top BridgeBio Pharma, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 9.42%
2Kohlberg Kravis Roberts & Co. L.P. 6.78%
3VIKING GLOBAL INVESTORS LP 6.01%
4FARALLON CAPITAL MANAGEMENT, L.L.C. 2.93%
5BlackRock 2.69%
6Aisling Capital Management LP 2.60%
7GEODE CAPITAL MANAGEMENT, LLC 2.48%
8Polar Capital Holdings Plc 2.45%
9Invesco 2.10%
10T. Rowe Price 1.82%

Reported BridgeBio Pharma, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

BridgeBio Pharma, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vanguard Group16,862,691 8.62%Form 13F, quarter ended March 31, 2026
BlackRock14,207,757 7.26%Form 13F, quarter ended March 31, 2026
Ali J. Satvat13,802,496 7.05%Proxy statement (DEF 14A), table as of April 1, 2026
KKR Genetic Disorder L.P.13,260,971 6.78%Proxy statement (DEF 14A), table as of April 1, 2026
JANUS HENDERSON GROUP PLC13,179,013 6.73%Schedule 13G, filed May 15, 2026
Viking Global Entities11,842,434 6.05%Proxy statement (DEF 14A), table as of April 1, 2026
VIKING GLOBAL INVESTORS LP9,792,219 5.00%Schedule 13D, filed July 10, 2026
NEIL KUMAR9,282,982 4.74%Schedule 13G, filed April 16, 2026
KKR Group Partnership L.P.9,232,739 4.72%Schedule 13D, filed August 17, 2026
State Street4,934,320 2.52%Form 13F, quarter ended March 31, 2026

Percentages above are of 195,707,702 shares outstanding, as reported by BridgeBio Pharma, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At BridgeBio Pharma, Inc.'s shareholder meeting held June 22, 2026, in the 2025-2026 proxy season, 465 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 4,402 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — BridgeBio Pharma, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BridgeBio Pharma, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 26, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BridgeBio Pharma, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

BridgeBio Pharma, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “BridgeBio Pharma (BBIO) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/bridgebio-pharma-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.